<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19523312</article-id>
      <article-id pub-id-type="pmc">2727341</article-id>
      <article-id pub-id-type="publisher-id">08-1006</article-id>
      <article-id pub-id-type="doi">10.3201/eid1506.081006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Extensively Drug-Resistant <italic>Acinetobacter baumannii</italic></article-title>
        <alt-title alt-title-type="running-head">Extensively Drug-Resistant <italic>Acinetobacter baumanniii</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Doi</surname>
            <given-names>Yohei</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Husain</surname>
            <given-names>Shahid</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Potoski</surname>
            <given-names>Brian A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McCurry</surname>
            <given-names>Kenneth R.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paterson</surname>
            <given-names>David L.</given-names>
          </name>
        </contrib>
        <aff id="aff1">University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA (Y. Doi, B.A. Potoski, D.L. Paterson)</aff>
        <aff id="aff2">University of Toronto, Toronto, Ontario, Canada (S. Husain)</aff>
        <aff id="aff3">Toronto General Hospital, Toronto (S. Husain)</aff>
        <aff id="aff4">Cleveland Clinic, Cleveland, Ohio, USA (K.R. McCurry)</aff>
        <aff id="aff5">University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia (D.L. Paterson)</aff>
        <aff id="aff6">Royal Brisbane and Women&#x2019;s Hospital, Brisbane (D.L. Paterson)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Yohei Doi, University of Pittsburgh Medical Center, S829 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, USA; email: <email xlink:href="yod4@pitt.edu">yod4@pitt.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2009</year>
      </pub-date>
      <volume>15</volume>
      <issue>6</issue>
      <fpage>980</fpage>
      <lpage>982</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Acinetobacter baumannii</kwd>
        <kwd>bacteria</kwd>
        <kwd>antimicrobial resistance</kwd>
        <kwd>extensively drug resistant</kwd>
        <kwd>colistin</kwd>
        <kwd>Pennsylvania</kwd>
        <kwd>USA</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> In the 1990s, patients infected with vancomycin-resistant <italic>Enterococcus faecium</italic> were successfully treated with new antimicrobial drugs. However, it is unlikely that new antimicrobial drugs will be available in the near future to treat patients infected with gram-negative pathogens such as <italic>Acinetobacter baumannii</italic> (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). No new antimicrobial drugs active against this organism are currently in clinical trials (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>). We report a patient infected with <italic>A</italic>. <italic>baumannii</italic> that lacked susceptibility to all commercially available antimicrobial drugs.</p>
    <p>The patient, a 55-year-old woman, had a prolonged stay in an intensive care unit at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) after undergoing lung transplantation. In the tenth postoperative week, ventilator-associated pneumonia developed, which was caused by <italic>A</italic>. <italic>baumanni</italic> that lacked susceptibility to all antimicrobial drugs tested except colistin (MIC 0.5 &#x3BC;g/mL). Therapy with colistin and tigecycline was begun. Colistin was administered intravenously and by inhalation. Although the pneumonia showed radiographic response to the antimicrobial drug therapy, <italic>A</italic>. <italic>baumannii</italic> continued to be isolated from respiratory secretions on numerous occasions. Despite another course of therapy with colistin and cefepime, the patient never recovered from respiratory failure. She eventually died of sepsis caused by vancomycin-resistant <italic>E</italic>. <italic>faecium</italic>. An <italic>A</italic>. <italic>baumannii</italic> isolate obtained just before she died lacked susceptibility to all commercially available antimicrobial drugs (<xref ref-type="table" rid="T1">Table</xref>).</p>
    <table-wrap id="T1" position="float">
      <label>Table</label>
      <caption>
        <title>MICs and antimicrobial drug susceptibility for an extensively drug-resistant strain of <italic>Acinetobacter baumannii</italic>*</title>
      </caption>
      <table frame="hsides" rules="groups">
        <col width="128" span="1"/>
        <col width="90" span="1"/>
        <col width="97" span="1"/>
        <thead>
          <tr>
            <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Drugs</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">MIC, &#x3BC;g/mL</th>
            <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Interpretation</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Carbapanems</td>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Imipenem</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Meropenem<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Penicillins</td>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ampicillin/sulbactam</td>
            <td valign="top" align="center" rowspan="1" colspan="1">32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Piperacillin/tazobactam<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cephalosporins</td>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ceftazidime</td>
            <td valign="top" align="center" rowspan="1" colspan="1">48</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cefepime<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">16<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Intermediate<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Aminoglycosides</td>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gentamicin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tobramycin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Amikacin<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256<hr/></td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant<hr/></td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Others</td>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
            <td valign="top" align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ciprofloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tigecycline</td>
            <td valign="top" align="center" rowspan="1" colspan="1">2</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Intermediate</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Colistin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;1,024</td>
            <td valign="top" align="center" rowspan="1" colspan="1">Resistant</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>*Susceptibility testing was performed by using the Etest (AB Biodisk, Solna, Sweden), except for colistin, for which the standard agar dilution method was used. Interpretation was according to breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA). No tigecycline breakpoints for <italic>Acinetobacter</italic> spp. are provided by the CLSI, the European Committee on Antimicrobial Susceptibility Testing (Basel, Switzerland), or the US Food and Drug Administration (Silver Spring, MD, USA). Breakpoints of the British Society for Antimicrobial Chemotherapy (Birmingham, UK) are indicated for tigecycline.</p>
      </table-wrap-foot>
    </table-wrap>
    <p>Multidrug-resistant <italic>A</italic>. <italic>baumannii</italic> has emerged as a substantial problem worldwide (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). Such strains are typically resistant to all &#x3B2;-lactams and fluoroquinolones and require salvage therapy with colistin, amikacin, or tigecycline. Unfortunately, notably high-level resistance to colistin and amikacin was found in the isolate we have described (<xref ref-type="table" rid="T1">Table</xref>). Tigecycline, a newly available glycylcycline antimicrobial drug, showed intermediate susceptibility. No randomized trials have been performed to specifically evaluate combination antimicrobial drug therapy for treatment of infection with <italic>A</italic>. <italic>baumannii</italic>.</p>
    <p>Considerable media attention has been paid to extensively drug-resistant (XDR) strains of <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>). Infections with XDR strains are extremely difficult to treat and pose considerable infection control issues. We recently proposed that gram-negative bacilli lacking susceptibility to all commercially available antimicrobial drugs also be referred to as XDR because no therapeutic options are available (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>).</p>
    <p>Numerous outbreaks of <italic>A</italic>. <italic>baumannii</italic> infection have been reported worldwide (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). Unfortunately, multidrug-resistant <italic>A</italic>. <italic>baumannii</italic> strains have become endemic in some institutions. Experimental and clinical isolates lacking susceptibility to colistin, often considered the drug of last resort, are increasingly being reported (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>&#x2013;<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). Therefore, we alert healthcare workers to the need for stringent care in adhering to infection control precautions when caring for patients infected with XDR <italic>A</italic>. <italic>baumannii</italic>. Use of contact isolation precautions, enhanced environmental cleaning, removal of sources of infection from the hospital environment, and prudent use of antimicrobial drugs can contribute to control of such outbreaks (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). Fortunately, no spread of the XDR strain affecting this patient occurred. A crisis is looming should XDR <italic>A</italic>. <italic>baumannii</italic> become established pathogens in hospitals.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant <italic>Acinetobacter baumannii</italic> [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jun [<italic>date cited</italic>]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/15/6/980.htm">http://www.cdc.gov/EID/content/15/6/980.htm</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <p>Y.D. was supported by National Institutes of Health (NIH) training grant T32AI007333, and D.L.P. was supported in part by NIH research grant R01AI070896.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Talbot</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Bradley</surname> <given-names>J</given-names></string-name>, <string-name><surname>Edwards</surname> <given-names>JE</given-names> <suffix>Jr</suffix></string-name>, <string-name><surname>Gilbert</surname> <given-names>D</given-names></string-name>, <string-name><surname>Scheld</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bartlett</surname> <given-names>JG</given-names></string-name> <article-title>Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.</article-title><source>Clin Infect Dis</source> <year>2006</year>;<volume>42</volume>:<fpage>657</fpage>&#x2013;<lpage>68</lpage> <pub-id pub-id-type="doi">10.1086/499819</pub-id><pub-id pub-id-type="pmid">16447111</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Perez</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hujer</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Hujer</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Decker</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Rather</surname> <given-names>PN</given-names></string-name>, <string-name><surname>Bonomo</surname> <given-names>RA</given-names></string-name> <article-title>Global challenge of multidrug-resistant <italic>Acinetobacter baumannii.</italic></article-title><source>Antimicrob Agents Chemother</source> <year>2007</year>;<volume>51</volume>:<fpage>3471</fpage>&#x2013;<lpage>84</lpage> <pub-id pub-id-type="doi">10.1128/AAC.01464-06</pub-id><pub-id pub-id-type="pmid">17646423</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Maartens</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wilkinson</surname> <given-names>RJ</given-names></string-name> <article-title>Tuberculosis.</article-title><source>Lancet</source> <year>2007</year>;<volume>370</volume>:<fpage>2030</fpage>&#x2013;<lpage>43</lpage> <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61262-8</pub-id><pub-id pub-id-type="pmid">17719083</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Paterson</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Doi</surname> <given-names>Y</given-names></string-name> <article-title>A step closer to extreme drug resistance (XDR) in gram-negative bacilli.</article-title><source>Clin Infect Dis</source> <year>2007</year>;<volume>45</volume>:<fpage>1179</fpage>&#x2013;<lpage>81</lpage> <pub-id pub-id-type="doi">10.1086/522287</pub-id><pub-id pub-id-type="pmid">17918079</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Fournier</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Richet</surname> <given-names>H</given-names></string-name> <article-title>The epidemiology and control of <italic>Acinetobacter baumannii</italic> in health care facilities.</article-title><source>Clin Infect Dis</source> <year>2006</year>;<volume>42</volume>:<fpage>692</fpage>&#x2013;<lpage>9</lpage> <pub-id pub-id-type="doi">10.1086/500202</pub-id><pub-id pub-id-type="pmid">16447117</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>David</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Gill</surname> <given-names>MJ</given-names></string-name> <article-title>Potential for underdosing and emergence of resistance in <italic>Acinetobacter baumannii</italic> during treatment with colistin.</article-title><source>J Antimicrob Chemother</source> <year>2008</year>;<volume>61</volume>:<fpage>962</fpage>&#x2013;<lpage>4</lpage> <pub-id pub-id-type="doi">10.1093/jac/dkn009</pub-id><pub-id pub-id-type="pmid">18238890</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Ko</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Suh</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Kwon</surname> <given-names>KT</given-names></string-name>, <string-name><surname>Jung</surname> <given-names>SI</given-names></string-name>, <string-name><surname>Park</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Kang</surname> <given-names>CI</given-names></string-name>, <etal/><article-title>High rates of resistance to colistin and polymyxin B in subgroups of <italic>Acinetobacter baumannii</italic> isolates from Korea.</article-title><source>J Antimicrob Chemother</source> <year>2007</year>;<volume>60</volume>:<fpage>1163</fpage>&#x2013;<lpage>7</lpage> <pub-id pub-id-type="doi">10.1093/jac/dkm305</pub-id><pub-id pub-id-type="pmid">17761499</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Tan</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Li</surname> <given-names>J</given-names></string-name>, <string-name><surname>Nation</surname> <given-names>RL</given-names></string-name> <article-title>Activity of colistin against heteroresistant <italic>Acinetobacter baumannii</italic> and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.</article-title><source>Antimicrob Agents Chemother</source> <year>2007</year>;<volume>51</volume>:<fpage>3413</fpage>&#x2013;<lpage>5</lpage> <pub-id pub-id-type="doi">10.1128/AAC.01571-06</pub-id><pub-id pub-id-type="pmid">17620384</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
